Summarized by Masters of Longevity from Longevity Technology.
A news article about a biotech patenting a dual-gene therapeutic strategy aimed at treating aging-related biology, explaining the concept and implications.
Key Takeaways
- BioViva obtained a US patent covering a combined gene therapy using hTERT and Follistatin-344 to target aging-related biological processes.
- The patent secures intellectual property rights but does not indicate regulatory approval, safety, or demonstrated clinical efficacy.
- Targeting shared aging mechanisms could potentially shift multiple age-related diseases' trajectories if preclinical and clinical validation succeeds.
